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A B S T R A C T
Objectives: The aim of this study was to determine the percentage of antimicrobial-resistant isolates and
the associated resistance mechanisms in Gram-negative bacteria from South Western Nigeria.
Methods: A total of 306 non-duplicate unbiased Gram-negative isolates were recovered from patients
admitted to three teaching hospitals in South Western Nigeria in 2011 and 2013. Isolates were from
clinical samples as well as from stool samples of inpatients without infection to assess antimicrobial
resistance patterns in carriage isolates. Antimicrobial susceptibility testing was performed, and PCR and
sequencing were used to identify genes encoding various known β-lactamases. Based on phenotypic and
genotypic results, 10 isolates representing the diversity of phenotypes present were selected for whole-
genome sequencing (WGS).
Results: Antimicrobial susceptibility testing revealed the following resistance rates: fluoroquinolones,
78.1%; third-generation cephalosporins, 92.2%; and carbapenems, 52.6%. More resistant isolates were
isolated from stools of uninfected patients compared with clinical infection specimens. Klebsiella (10%)
and Escherichia coli (7%) isolates produced a carbapenemase. WGS of selected isolates identified the
presence of globally disseminated clones.
Conclusion: This study illustrates a crisis for the use of first-line antimicrobial therapy in Nigerian
patients. It is likely that Nigeria is playing a significant role in the spread of antimicrobial resistance
owing to its large population with considerable global mobility.
© 2019 International Society for Antimicrobial Chemotherapy. Published by Elsevier Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Nigeria and other sub-Saharan African countries are facing an
increasing number of healthcare-associated infections caused by
multidrug-resistant Gram-negative bacteria (GNB) [1]. Pathogenic
species have evolved resistance to multiple antimicrobial agents
including the mainstays of treatment [2,3]. This is of concern as
there are few new antibiotics in the development pipeline with
activity against GNB [4].
Carbapenems have become a mainstay of therapy for the
treatment of extended-spectrum β-lactamase (ESBL)-producing
GNB, leading to an increase in carbapenem use for the treatment of
serious infections [5]. As a result, there has been a selective
pressure for carbapenem resistance, and carbapenem-resistant* Corresponding author. Present address: Department of Biomedical Sciences,
Ladoke Akintola University of Technology, Ogbomosho, Osogbo Campus, Nigeria.
E-mail address: doogbolu@lautech.edu.ng (D.O. Ogbolu).
http://dx.doi.org/10.1016/j.jgar.2019.10.016
2213-7165/© 2019 International Society for Antimicrobial Chemotherapy. Published by
creativecommons.org/licenses/by-nc-nd/4.0/).strains have spread globally [6]. Worryingly, carbapenem-resistant
bacteria are often also resistant to other classes of antibiotics
including aminoglycosides, fluoroquinolones and other β-lactams,
often with colistin and tigecycline as the only effective drugs.
Resistance to both of these antibiotics can also evolve easily,
making them unreliable as ‘last-resort’ therapies [7].
GNB cause a significant number of infections in Nigerian
hospitals and represent the majority of isolates both from wounds
and urinary tract infections; these form the largest group of clinical
specimens received in Nigerian clinical microbiology laboratories
[1]. Carbapenem-resistant GNB have become prevalent in many
parts of the world, including Nigeria and sub-Saharan Africa.
However, to our knowledge there are few data and no organised
antimicrobial resistance surveillance networks for Africa. Recently,
we showed that carbapenem-resistant bacteria are present in
Nigeria. However, details of the strains with this phenotype and
the mechanisms of resistance have not been studied in detail [2,3].
The potential role of the Nigerian population in the global
spread of antimicrobial resistance is great, but the local situation is Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
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determine the percentage of antimicrobial-resistant clinical and
commensal isolates and the associated resistance mechanisms in
GNB from South Western Nigeria.
2. Materials and methods
2.1. Sample sites and bacterial isolates
Most of the Nigerian population is located in the southwest of
the country, which is also where the major transportation hubs
are located. GNB isolates for this study were recovered from
patients admitted to three large teaching hospitals located in
three states of South Western Nigeria from a range of clinical
specimens from invasive infections and colonisation (Table 1 and
Fig. 1). Olabisi Onabanjo University Teaching Hospital is a 185-bed
tertiary healthcare centre and a major referral centre for Ogun
State. University College Hospital, Ibadan, is an 850-bed federal
teaching hospital in Oyo State. Obafemi Awolowo University
Teaching Hospitals Complex is a 535-bed teaching hospital in
Osun State.
In addition, isolates from stool samples sent for routine
examination from patients without infection were also collected.
Isolates were non-duplicate and unbiased (i.e. no selective criteria
beyond being a GNB species were applied) and were randomly
collected from the hospital laboratories in 2011 and 2013. A total of
306 isolates were recovered. No information regarding the
antimicrobial susceptibility of any of the isolates was used as an
inclusion criterion. The isolates comprised Escherichia coli,
Klebsiella spp., Pseudomonas aeruginosa, Proteus spp. and others
(Serratia, Citrobacter spp. and Providencia rettgeri). Species assign-
ment was confirmed for all isolates using standard biochemical
tests and using API 20E strips (bioMérieux, Basingstoke, UK) for
Enterobacteriaceae.
2.2. Antimicrobial susceptibility testing
Antimicrobial susceptibility of the isolates to a panel of
antibiotic classes commonly used in the study hospitals, such as
fluoroquinolones, third-generation cephalosporins and carbape-
nems, was determined by the disc diffusion method on Mueller–
Hinton agar using antibiotic disks from Oxoid Ltd. (Basingstoke,
UK) according to European Committee on Antimicrobial Suscepti-
bility Testing (EUCAST) recommendations and interpreted accord-
ing to EUCAST breakpoints [8]. All antimicrobial susceptibility
testing included the control organisms E. coli NCTC 10418 and P.
aeruginosa NCTC 10662.Table 1
Distribution and sources of bacterial isolates.
Specimen type No. of isolates
Klebsiella spp. Escherichia coli P
Wound 42 9 2
Urine 38 26 8
Blood culture 8 3 0
Sputum 7 2 1
HVS/ECS 2 3 0
Ear swab 6 0 1
Catheter 6 1 2
Aspirate 4 0 3
Other 0 0 1
Total 113 44 5
Stoola 9 52 6
Total (overall) 122 96 6
HVS/ECS, high vaginal swab/endocervical swab.
a Stool samples from healthy carriers.2.3. Identification of carbapenemase production
Enterobacteriaceae isolates were tested for carbapenemase
production using the disc-based Carbapenemase Detection Set
(Mast Group, Bootle, UK) and the results were interpreted using
the Carbapenemase Detection Set Calculator (Mast Group) tool as
per the manufacturer's guidelines.
2.4. Identification of known carbapenemase genes
Bacterial DNA was extracted by the crude boiling method. PCR
and sequencing were used to identify genes encoding various
known β-lactamases (including carbapenemases, NDM, VIM, KPC
and GES) using the primers shown in Supplementary Table S1.
2.5. Random amplified polymorphic DNA (RAPD)-PCR
An RAPD-PCR typing approach was used for each species as a
rapid and inexpensive way to assess the diversity of strains within
each population. The primer sequences and PCR conditions used
were according to Vogel et al. [9], modified to use 1 mL of 100 mM
of primers at a final concentration of 0.02 mM. The experiment was
repeated to ensure reproducibility.
2.6. Whole-genome sequencing (WGS) and bioinformatics analysis
To characterise the strain types, plasmid content and type of
antimicrobial resistance genes present in the isolate collection, 10
isolates (a lack of resources limited the number sequenced) were
selected for WGS based on their antimicrobial profile, carbapene-
mase production, genotype, clinical specimen, source and species.
DNA was extracted using a QIAamp1 DNA Mini Kit (QIAGEN,
Crawley, UK) according to the manufacturer's instructions. Paired-
end Illumina sequencing was used to generate 250-bp high-quality
reads. The genome was assembled using Velvet [10] and contigs
were re-ordered against relevant reference genomes using MAUVE
[11]. Assemblies were annotated using Rapid Annotation using
Subsystem Technology (RAST) (http://rast.nmpdr.org/rast.cgi).
Assemblies were used to search for plasmid content and to
determine multilocus sequence typing (MLST) sequence types
using the PlasmidFinder and MLST tools hosted at the Centre for
Genomic Epidemiology (https://cge.cbs.dtu.dk/services/Plasmid-
Finder and http://cge.cbs.dtu.dk/services/MLST, respectively). The
Comprehensive Antibiotic Resistance Database (CARD) was
searched to identify antimicrobial resistance genes [12]. Specific
assembly of plasmids was attempted using plasmidSPAdes, and
plasmid content was identified by plasmid network reconstructionseudomonas spp. Proteus spp. Other Total
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Fig. 1. Summary of antimicrobial resistance rates in South Western Nigeria. Pie charts show the proportion of isolates classified as resistant (R) or susceptible (S) to
fluoroquinolones (FQ, blue and red), third-generation cephalosporins (3GC, red and white) and carbapenems (Carb, green and yellow). The left-hand figure shows data for the
whole study (including all species and both years). The expanded insert (righthand side) shows data from each of the three hospitals (grey circles). UCH, University College
Hospital (Ibadan); OOUTH, Olabisi Onabanjo University Teaching Hospital (Sagamu); OAUTHC, Obafemi Awolowo University Teaching Hospitals Complex (Ife).
Table 2
Overview of antimicrobial susceptibility testing to clinically important antibiotics.
No. of isolates Resistant isolates (%)
FQ 3GC CARB
Total isolates 306 78.1 92.2 52.6
Klebsiella spp. 122 75.4 92.6 50.8
Escherichia coli 96 81.4 93.7 59.4
Pseudomonas spp. 60 76.7 91.7 51.7
Proteus spp. 24 83.3 87.5 45.8
Others 4 75.0 75.0 0
Clinical samples 238 80.4 90 47.8
Klebsiella spp. 113 70.8 89.4 53.1
E. coli 44 77.2 84.1 40.9
Pseudomonas spp. 54 83.3 88.9 46.3
Proteus spp. 23 78.3 87 47.8
Others 4 75 75 0
Stool (healthy individuals) 68 69.1 100 69.1
Klebsiella spp. 9 100 100 0
E. coli 52 76.9 96.2 75
Pseudomonas spp. 6 16.7 100 83.3
Proteus spp.a 1 N/A N/A N/A
Others 0 – – –
By year of isolation
2011 182 78.5 96.6 59.3
2013 124 76.9 86.8 43.0
By location
Hospital I (UCH) 212 80.9 100 50
Hospital II (OOUTH) 6 83.3 100 50
Hospital III (OAUTHC) 20 75 90 55
FQ, fluoroquinolones; 3GC, third-generation cephalosporins; CARB, carbapenems;
N/A, not applicable; UCH, University College Hospital (Ibadan); OOUTH, Olabisi
Onabanjo University Teaching Hospital (Sagamu); OAUTHC, Obafemi Awolowo
University Teaching Hospitals Complex (Ife).
a Percentage not calculated because of the small number.
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When necessary, reads were mapped against assemblies using
Bowtie [14] and were visualised in Artemis [15].
3. Results
3.1. Antimicrobial resistance in Nigerian isolates
Among the entire collection of 306 isolates, 78.1% were resistant
to fluoroquinolones, 92.2% to third-generation cephalosporins and
52.3% to carbapenems (Table 2). The high percentages of clinical
isolates resistant to these drug classes were very similar in all three
study sites (fluoroquinolone resistance, 75–83%; third-generation
cephalosporin resistance, 90–100%; and carbapenem resistance,
50–55%).
Of concern was the observation that the percentages of isolates
from stool samples of uninfected patients, i.e. those being carried
as commensal bacteria, that were resistant to third-generation
cephalosporins (100%) and carbapenems (69.1%) was actually
higher than in isolates from patients being treated for an infection.
The percentages of resistant isolates both from commensal and
clinical samples are shown in Table 2.
When stratified by species, E. coli were most commonly
resistant to third-generation cephalosporins (93.7%) and carba-
penems (59.4%), followed by Pseudomonas spp. (91.7% resistant
to third-generation cephalosporins and 51.7% to carbapenems)
(Table 2). Of the 306 isolates, no species had 50% of isolates
that were susceptible to all three classes of antibiotic. Proteus
spp. isolates (n = 24) were least likely to be carbapenem-
resistant; none the less, 45.8% of these isolates were resistant
to this class of drug.
Isolates in this study were collected in two different years (2011
and 2013) and the percentages of fluoroquinolone-resistant
isolates in the two years were very similar. However, the
percentages of isolates resistant to cephalosporins in the two
years decreased from 96.6% to 86.8% and the percentage of isolates
resistant to carbapenems decreased from 59.3% to 43.0% (Table 2).3.2. Typing of isolates
RAPD-PCR was used to type 54 of the isolates, representing 18
each of E. coli, Klebsiella pneumoniae and P. aeruginosa. A wide
variety of patterns were observed for each species, with only a
small number of repeated patterns observed. For example,13 RAPD
Fig. 2. Random amplified polymorphic DNA (RAPD) analysis of a selection of 18 E. coli isolates. Agarose gel electrophoresis of amplimers from RAPD-PCR. M, marker. The bold
line above the gel shows four isolates with an identical banding pattern.
Table 3
Carbapenemase production and presence of carbapenemase genes.
Species No. of isolates No. of carbapenem-resistant isolates No. of isolates with phenotypic
carbapenemase activity
No. of isolates with carbapenemase genes
by PCR
+ve –ve blaVIM blaGES blaNDM
Klebsiella spp.a 122 62 34 28 2 3 2
Escherichia coli 96 57 32 25 3 1 0
Pseudomonas spp.a 60 31 22 9 4 6 0
Proteus spp. 24 11 5 6 0 0 0
Other 4 0 N/A N/A 0 0 0
Total 306 161 93 68 9 10 2
N/A, not applicable.
a Two isolates carried two carbapenemase genes; Klebsiella spp., NDM + VIM; and Pseudomonas spp., GES + VIM.
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lack of dominance by specific clones (Fig. 2).
3.3. Carbapenemase production and identification of carbapenemase
genes
Although 40–60% isolates were phenotypically carbapenem-
resistant, only 19 (6.2%) of the 306 isolates carried a known
carbapenemase gene. Specific carbapenemase genes were ampli-
fied by PCR and the genes were verified by DNA sequencing. PCR
revealed the presence of variants of VIM (n = 9), GES (n = 10) and
NDM (n = 2) families (Table 3). These genes were detected in K.
pneumoniae (n = 6), E. coli (n = 4) and P. aeruginosa (n = 9) isolates.
Two isolates carried two carbapenemase genes (blaNDM+ blaVIM
and blaGES + blaVIM). The blaKPC, blaIMP and blaOXA-48 genes were not
detected in any isolate.
Since 161 (52.6%) of the 306 isolates were resistant to carbapenems
but most did not appear to produce a known carbapenemase, the
presence of other known resistance mechanisms was investigated.
Primers specific for each of the CTX-M subgroups were used to detect
various CTX-M genes. Of the total 218 E. coli and K. pneumoniae
isolates, 173 (79.4%) contained a CTX-M allele. DNA sequencing of a
random selection of 40 isolates revealed all to be CTX-M-15. None of
these isolates demonstrated phenotypic derepression of efflux, but
all showed either complete loss or reduced production of outer
membrane porins (data not shown).
3.4. Characterisation of antimicrobial resistance mechanisms and
strain types in representative isolates
WGS of 10 isolates, including two K. pneumoniae, two E. coli,
three P. aeruginosa, two Proteus mirabilis and one P. rettgeri isolate
(Table 4), identified some globally established strain types incirculation in Nigeria, notably K. pneumoniae ST11 and P. aeruginosa
ST224 and ST233.
Both of the K. pneumoniae isolates belonged to ST11 and were
from urine of different patients in 2011 from University College
Hospital, Ibadan. Both genome assemblies were essentially
identical, and both carried blaNDM-1 and blaCTX-M-15 (Table 4). In
addition, both isolates also carried blaOXA-1 and blaSHV-11. Interest-
ingly, there was direct evidence for mobility of the blaNDM-1 gene in
this strain. Whilst the NDM-1-encoding gene was detected by PCR
using a boiled colony preparation as a template in both isolates
(U52 and U37), in both genome assemblies created after
sequencing of isolated DNA preparations it was only initially seen
in the genome assembly for U52. Analysis of the genetic location of
this gene showed it to be present in a context similar to that
previously observed by others in an operon with bleMBL and
associated with trpF, dsbC and cutA (Fig. 3). This region was absent
in isolate U37, and no sequence reads mapped against the U52
reference (Supplementary Fig. S1), demonstrating likely mobility
of this whole region as has been suggested previously [16]. IncFIB
and FII plasmid replicons were present in both strains, supporting a
plasmidic context for blaNDM-1 (Fig. 3). In addition to the β-
lactamase genes, both isolates also carried resistance genes to
trimethoprim (dfrA12), macrolides (mphA), aminoglycosides
(rmtF), chloramphenicol (cat) and sulfonamides (sul1). Consistent
with fluoroquinolone resistance, mutations in gyrA were observed.
One of the P. aeruginosa isolates belonged to ST244 and carried
the mutant PDC-1 AmpC enzyme as well as genes contributing to
resistance to chloramphenicol (cmx, catB7), aminoglycosides [aph
(3ʹʹ)-I1, aph(6)-Id] and fosfomycin (fosA). The other two isolates
were both members of ST233 and both carried blaPDC-3. These latter
two isolates also carried blaVIM-2 and blaOXA-33, were of the same
MLST type and were both isolated from Olabisi Onabanjo
University Teaching Hospital although 2 years apart. Reads from
Fig. 3. (a) Plasmid content reconstructed using PLACNET. Panel (A) shows the network from P. aeruginosa F46 with a chromosomal network of 60 contigs totalling 6.7 Mb
and three discrete plasmid networks (P1–P3); P1 and P2 are both <5 kb, and P3 carrying VIM-2 consists of 8 contigs of 31 kb. The blaVIM-2 gene in Pseudomonas was present
on a small contig with homology to an integron. Trimethoprim and aminoglycoside resistance genes were also present in the assembled contig. Panel (B) shows the network
from K. pneumoniae U52 with a chromosomal group of 87 contigs totalling 5.3 Mb and four plasmid networks (P1–P4); P1 and P3 are both 5 kb, P2 is 9 kb, and P4 consists of a
large network of 90 contigs totalling 1.9 Mb which is likely to represent more than one IncF type plasmid that have not been resolved. The blaNDM-1 gene in U52 was on a small
contig in an operon with the ble gene. (b) Immediately downstream of blaNDM-1 in isolate U52 were the trpF, dsbC and cutA genes.
Table 4
Strain types, β-lactamase genes and plasmid replicons present in representative isolates.
Strain Species MLST MIC (mg/mL) Carbapenemase gene(s) β-Lactamase gene(s) Plasmid replicon(s)
IPM MEM ETP
U37 Klebsiella pneumoniae ST11 16 16 64 blaNDM-1 blaOXA-1, blaSHV-11, blaCTX-M-15 FIB (K), FII (K)
U52 K. pneumoniae ST11 16 16 64 blaNDM-1 blaOXA-1, blaSHV-11, blaCTX-M-15 FIB (K), FII (K)
S46 Escherichia coli ST226 16 0.12 0.12 – blaAmpC, blaTEM-1 FII
F124 E. coli ST156 0.5 0.06 0.06 – blaTEM-1, blaACT-7 Q1
F19 Pseudomonas aeruginosa ST244 8 8 N/D blaPDC-1 – –
F46 P. aeruginosa ST233 32 64 N/D blaVIM-2, blaPDC-3 blaOXA-33 –
U36 P. aeruginosa ST233 64 32 N/D blaVIM-2, blaPDC-3 blaOXA-33 –
F10 Proteus mirabilis – 8 0.25 2 – blaCMY-41, blaCMY-31, blaTEM-1 Q1
F56 P. mirabilis – 8 0.25 0.25 – blaACT-7, blaTEM-1 Q1, Col(BS512)
S39 Providencia rettgeri – 16 2 4 – blaSRT-2 –
MLST, multilocus sequence typing; MIC, minimum inhibitory concentration; IPM, imipenem; MEM, meropenem; ETP, ertapenem.
N/D, not determined (as Pseudomonas spp. are intrinsically resistant to ETP).
–Indicates no gene or replicon detected, or for sequence type a species where no MLST scheme has been established.
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SPAdes (using the plasmidSPAdes option); both resulted in
assemblies with the blaVIM-2 gene present on a contig of
7000 bp. When this sequence was compared with known
sequences in GenBank using the BLAST algorithm, a perfect match
for an integron carrying blaVIM-2 was found (accession no.
KT768111.1). Fig. 3 shows a plasmid network reconstruction and
the genetic context of the blaVIM-2 gene in these two isolates.
The two E. coli strains sequenced belonged to ST226 and ST156.
Neither carried known carbapenemase genes, although both had
multiple mutations within ampD suggesting de-repression of the
chromosomal ampC gene. Both strains also carried blaTEM-1 and
various other mobile resistance genes including genes conferring
aminoglycoside resistance [aph(6)-Id, aph(3ʹʹ)-I1]. An IncFII plas-
mid replicon was present in isolate S46 (the ST226 isolate).
Two P. mirabilis strains were sequenced. Isolate F10 carried two
blaCMY genes, namely blaCMY-41 reported once previously in a
Citrobacter freundii isolated from food in Egypt [17] and blaCMY-31
previously reported in Klebsiella and Salmonella [18,19]. A Q1
plasmid replicon was present in isolate F10. This isolate also
carried two separate aminoglycoside [aadA5, aph(3ʹʹ)-I1], chlor-
amphenicol (catI) and sulfonamide (sul1) resistance genes as well
as a plasmid-mediated quinolone resistance gene (qnrA1). Proteus
mirabilis isolate F56 was found to carry a novel CMY enzyme with a
single substitution (glutamic acid for aspartic acid at codon 144)
distinguishing this protein from CMY-48 isolated from C. freundii.
Isolate F56 also carried a chloramphenicol acetyltransferase gene
(catI) and three aminoglycoside resistance genes [aadA5, aph(3ʹʹ)-
I1 and aph(6)-Id].
The sequenced P. rettgeri isolate (S39) carried an SRT-2 AmpC β-
lactamase variant that has previously been described in Serratia
marcescens [20]. No other β-lactamase genes or plasmid replicons
were detected in this isolate.
4. Discussion
4.1. Population density of study areas
The studycoveredthe southwestofNigeria,wherethepopulation
density of the country is highest with 50 million people. The study
area included major population centres close to other major cities
with a diverse population in terms of culture, race, religion and social
standing. The major international transportation hubs of Nigeria are
also in the southwest of the country and more than 15,200
international flights leave annually to over 32 airports in 30 different
countries, and more than 8.3 million passengers fly through Nigeria
annually [21]. International destinations are varied, with Europe and
the Middle East being most common, followed by destinations in
Asia, and a smaller number of flights departing to North and South
America [21].
4.2. Antimicrobial resistance of isolates
This study showed that there is a very high prevalence of
resistance among Nigerian GNB isolates to three key classes of
antibiotic. A high frequency of resistance to fluoroquinolones and
cephalosporins has been seen in other areas of the world,
increasing the reliance on carbapenems for the treatment of
infections caused by GNB. In this study, >50% of the Nigerian
isolates were carbapenem-resistant, and empirical use of these
antibiotics for the treatment of serious infections is unlikely to be
effective. Resistant isolates were prevalent both in commensal
isolates from stools and clinical samples and were not restricted to
patients receiving antibiotic treatment for infections. From these
data, resistance to major antibiotics would appear to be the norm
in GNB carried by the Nigerian population.4.3. Mechanisms of carbapenem resistance
Characterisation of the mechanisms of carbapenem resistance
in the collection of isolates showed that some well-known and
globally disseminated carbapenemase genes are in circulation in
Nigeria, including NDM, VIM and GES enzymes. However, <10% of
the isolates in the study carried a known carbapenemase
(according both to molecular and phenotypic testing) and none
carried KPC or OXA family carbapenemases. Phenotypic detection
of carbapenemase production agreed well with detection of genes
by PCR and sequencing. All isolates with known carbapenemase
genes showed phenotypic carbapenemase activity. A recent report
from Edo State (in South Nigeria, further east from the locations in
this study) reported the existence of OXA family carbapenemases
of OXA-48 and OXA-181 as well as NDM-1 [22]. Carbapenem
antibiotics are available in Nigeria but have historically not been
widely used in hospital medicine as they have not been part of the
common antibiotic formulary. Third-generation cephalosporins,
aminoglycosides and fluoroquinolones are the most prescribed
antibiotics in most Nigerian hospitals. There was essentially
pandrug resistance to the cephalosporins and fluoroquinolones in
the isolates in the current study. The high level of phenotypic
resistance to carbapenems in this collection could be the result of
carriage of carbapenemases that were not detectable by the
methods currently used. However, we hypothesise that the very
high frequency of carriage of ESBLs (80% of isolates of Enter-
obacteriaceae contained CTX-M variants) and AmpC variants in
combination with porin loss (in Pseudomonas isolates) selected by
prolonged and heavy cephalosporin usage are the cause of
carbapenem resistance in these isolates. A recent study described
Enterobacteriaceae isolates from the USA that were carbapenem
resistant without carriage of known carbapenemases [23].
4.4. Bacterial clones and antimicrobial resistance
Whilst local antibiotic use is likely to have made an impact on
the incidence of antimicrobial resistance in the collection of
isolates, globally disseminated strain types of high-risk clones, e.g.
K. pneumoniae ST11 and P. aeruginosa ST244 and ST233, encoding
important resistance genes were identified. This is highly relevant
given the mobility of the Nigerian population and the implications
of this mobility in global transfer of strains and genes. For example,
a recent case report documented a Canadian visitor who suffered a
lower leg fracture requiring surgical repair in Nigeria and was
repatriated 2 months later with a wound infected with Klebsiella,
Pseudomonas and E. coli isolates all carrying carbapenemases [24].
K. pneumoniae strains belonging to ST11 were detected. These
have been associated with the carriage of CTX-M-15 and KPC
enzymes, mainly in China. ST11 is also a single-locus variant of
ST258, which has been associated with the international dissemi-
nation of KPC enzymes on the pKPQIL plasmid [25]. ST258 isolates
have also been recently associated with NDM carriage in India,
Sweden and the UK [26]. In this study, E. coli ST226 was recovered
from an uninfected patient; this strain type has been found
circulating in highly resistant diarrhoeagenic E. coli in China. The
other E. coli ST identified (ST156) has previously been found in
Bangladesh [27] and in NDM-1-carrying clinical E. coli isolates
from the UK [28].
P. aeruginosa clone ST233 has been described as a dominant
international ‘high-risk clone’ amongst metallo-β-lactamase-pro-
ducing P. aeruginosa, and two blaVIM-2-positive isolates were found
in patients in the current study. Isolates of this ST have observed
seen in the UK [29] and have also been reported previously as
carrying blaVIM-2 or blaIMP-1 in Norway (in an isolate thought to be
imported from Ghana) [30], Japan [31] and South Africa [32]. The
other P. aeruginosa ST identified in this study (ST244) is a globally
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found to carry various carbapenemases including IMP and VIM
enzymes as well as ESBLs such as PER-1 and VEB-1 [33].
5. Conclusion
This study demonstrates that antimicrobial resistance in GNB in
Nigeria is commonplace and compromises the effectiveness of the
mainstays of broad-spectrum empirical therapy. Perhaps most
worryingly, this does not appear to be a problem restricted to
hospital patients, with resistance rates in commensal isolates
being equally high. Establishment of a reservoir of resistant strains
and antimicrobial resistance genes has occurred in Nigeria and this
reservoir is likely to be mobilised globally given the youthful
population and mobility of Nigerians. Data from the current study
underpin the urgent requirements for enhanced surveillance of
drug resistance in sub-Saharan Africa and the need for inter-
ventions to minimise the selection and transmission of antimicro-
bial-resistant GNB.
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